Cellular Immunotherapy Market Size Projected To Increase From $7.47 Billion To $12.49 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cellular Immunotherapy Market Size Outlook: How Fast Will Revenue Grow Through 2030?
In recent times, the market for cellular immunotherapy has expanded significantly. From a valuation of $6.56 billion in 2025, it is projected to reach $7.48 billion by 2026, reflecting a compound annual growth rate of 14.1%. The expansion observed in the historical period was driven by several key factors, including the achievements of initial CAR-T therapies, the existence of unaddressed requirements in oncology, an increase in research funding, the granting of regulatory approvals, and cooperative efforts between academia and industry.
The cellular immunotherapy market is anticipated to undergo rapid expansion over the coming years. By 2030, its valuation is projected to reach $12.5 billion, driven by a compound annual growth rate (CAGR) of 13.7%. This forecasted growth is largely fueled by advancements in solid tumor treatment, breakthroughs in NK cell therapy, the development of scalable manufacturing processes, the establishment of supportive regulatory environments, and heightened levels of oncology funding. Key trends shaping this period include the swift expansion of CAR-T cell therapies, the growing adoption of allogeneic cell treatments, an increased application in hematologic malignancies, notable progress in T cell engineering, and a surge in clinical trial activity.
Download A Free Sample Report For Comprehensive Market Insights:
Cellular Immunotherapy Market Industry Drivers: What Is Driving Revenue Growth?
The growing incidence of cancer is anticipated to drive expansion in the cellular immunotherapy market moving forward. Cancer encompasses a range of diseases marked by the abnormal, uncontrolled growth and dissemination of cells within the body. This upward trend in cancer prevalence can be attributed primarily to an aging demographic, lifestyle-related choices, and enhancements in screening and detection methods. Additionally, environmental factors and hereditary susceptibilities contribute significantly to higher occurrence rates. Cellular therapy strengthens the body’s immune defense against tumors by directly targeting malignant cells, thereby enhancing patient survival outcomes. When integrated with other therapeutic modalities, this strategy has the potential to lower both cancer incidence and recurrence rates. As an illustration, data from March 2024, released by MAC Clinical Research—a UK-based cancer research entity—shows that the number of individuals living with cancer in the United Kingdom is projected to climb from roughly 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer is fueling the growth of the cellular immunotherapy sector.
Cellular Immunotherapy Market Categorization By Product Type And Application
The cellular immunotherapy market covered in this report is segmented –
1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications
Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy
2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications
Cellular Immunotherapy Market Growth Trends: What Is Influencing The Future Outlook?
Key industry players in the cellular immunotherapy market are prioritizing innovations like immunotherapy to improve treatment effectiveness and broaden its use. Their efforts center on personalized medicine, combination therapies, and scalable manufacturing processes to enhance patient outcomes. Immunotherapy leverages the body’s own immune system to combat diseases, particularly cancer, by either amplifying immune responses or deploying targeted therapies that boost immune activity against specific cells. For example, in December 2023, Max Healthcare Institute Limited, a healthcare provider based in India, adopted CAR-T cell therapy—a groundbreaking cancer treatment that uses genetically modified T cells to precisely identify and destroy cancer cells. This personalized method achieves durable remission, especially for resistant blood cancers, while reducing harm to healthy tissues.
Cellular Immunotherapy Market Company Landscape And Strategic Competition
Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation
Access The Complete Cellular Immunotherapy Market Report:
Cellular Immunotherapy Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
